Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126473162 | 12647316 | 2 | F | 201606 | 20160809 | 20160812 | 20160816 | EXP | PHHY2016BR110108 | NOVARTIS | 91.32 | YR | F | Y | 52.00000 | KG | 20160816 | MD | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126473162 | 12647316 | 1 | PS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG [PATCH 5 (CM) 2], QD | Y | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126473162 | 12647316 | 2 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 9.5 MG [PATCH 10 (CM) 2], QD | Y | 22083 | 9.5 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126473162 | 12647316 | 3 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 13.3 MG [PATCH 15 (CM) 2], QD | Y | 22083 | 13.3 | MG | TRANS-THERAPEUTIC-SYSTEM | QD | |||||
| 126473162 | 12647316 | 4 | SS | EXELON PATCH | RIVASTIGMINE | 1 | Transdermal | 4.6 MG [PATCH 5 (CM) 2], QD | Y | 22083 | 4.6 | MG | TRANS-THERAPEUTIC-SYSTEM | QD |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126473162 | 12647316 | 1 | Dementia Alzheimer's type |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126473162 | 12647316 | HO |
| 126473162 | 12647316 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126473162 | 12647316 | Abasia | |
| 126473162 | 12647316 | Balance disorder | |
| 126473162 | 12647316 | Blood pressure increased | |
| 126473162 | 12647316 | Dysstasia | |
| 126473162 | 12647316 | Malaise | |
| 126473162 | 12647316 | Speech disorder | |
| 126473162 | 12647316 | Urinary tract infection | |
| 126473162 | 12647316 | Vomiting |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126473162 | 12647316 | 3 | 201605 | 0 | ||
| 126473162 | 12647316 | 4 | 20160725 | 0 |